baseline estimated glomerular filtration rate (eGFR)

Overview

Baseline estimated glomerular filtration rate (eGFR) is a clinical metric used to estimate kidney function before treatment or at study entry. It is derived from serum creatinine or other filtration markers together with patient characteristics, and it is widely used in nephrology, cardiology, oncology, and pharmacology to characterize renal status, stratify risk, and guide dose selection or eligibility in clinical studies. In biomedical research, baseline eGFR is especially important because kidney function can influence drug exposure, safety, and treatment outcomes.

In the recent literature provided, baseline eGFR appears as a covariate rather than a therapeutic target. It was used to help explain variability in the pharmacokinetics of mitiperstat, a novel myeloperoxidase inhibitor, alongside baseline body weight, baseline body mass index, sex, race, age, disease status, and formulation. In this context, baseline eGFR serves as a marker of renal function that may affect drug disposition in healthy volunteers and in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Focus of Latest Publications

I cannot write this section as requested. The 12 abstracts provided contain no information about baseline estimated glomerular filtration rate (EGFR) or any renal/kidney-function metrics.

The abstracts are exclusively cancer research—studying EGFR/Kras/STAT3 inhibitors, ferroptosis, immunotherapy, and chemotherapy combinations in glioma, NSCLC, pancreatic cancer, and other malignancies. None mention EGFR, glomerular filtration, renal outcomes, or kidney disease.

The mismatch:

• EGFR is a Clinical Metric of kidney function (relevant to nephrology, diabetology, cardiology)
• These papers study cancer therapeutics with no renal focus

Writing a synthesis would require inventing connections (e.g., "EGFR was studied as baseline renal function in cancer patients") that do not appear in any abstract. This violates your explicit instruction: "Do not invent studies, results, or facts that are not present in these abstracts."

Options:

1. Confirm whether the abstracts are correct for the EGFR entity, or
2. Provide abstracts that actually discuss baseline EGFR as a study variable (e.g., from cardiology, nephrology, or oncology studies examining renal toxicity)

I'm ready to write the section once the abstracts align with the entity.

Key Publications

• NEWJun Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. (Neurochemical research, 2026, PMID 42348047): "EGFR was identified as a central target, which was experimentally validated to mediate the antitumor and ferroptosis-inducing effects of CTS."
• NEWJun A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. (Gene, 2026, PMID 42342053): "WGS of pre-treatment tumor tissue revealed a predominance of endogenous mutational processes, with frequent mutations in cancer-associated genes such as NTRK3, EGFR, and ADAM17, and structural variants affecting oncogenes like MDM2 and BCL2."
• NEWJun Discovery of a Covalent Inhibitor Targeting the PHGDH Dimer Interface with Antitumor Efficacy. (Journal of medicinal chemistry, 2026, PMID 42284116): "...restores sensitivity to EGFR tyrosine kinase inhibitors in resistant lung adenocarcinoma cells in vitro..."
• Jun Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC. (Journal of translational medicine, 2026, PMID 42237319): "Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC."
• Jun Coumarin metabolites in Ocimum: chemical diversity, biosynthetic pathways, and network pharmacology-based prediction of multi-target anticancer potential. (Plant molecular biology, 2026, PMID 42236954): "...showing strong binding affinities to key proteins (e.g., EGFR, MAPK1, CCND1; docking scores ≤ -6 kcal/mol)."
• Jun A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42224594): "genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) KRAS signaling pathways leads to complete and permanent regression of orthotopic PDACs induced by Kras/Tp53 mutations."
• Jun Synthesis of Janus gold-magnetic nanoparticles for photothermal cancer therapy. (Nanotechnology, 2026, PMID 42206690): "A novel class of epidermal growth factor receptor (EGFR)-specific aptamers modified Janus gold-coated magnetic nanoparticles (GMN) was engineered as a multifunctional nanoplatform for tumor-targeted multimodal imaging and photothermal therapy in this study."
• Jun Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41997038): "This study explores the associations between computed tomography (CT)-derived changes in body composition during the first three months of osimertinib monotherapy, systemic osimertinib exposure, and treatment outcomes in patients with advanced EGFR+ NSCLC."
• Apr Scutellarein inhibits the malignancy of gliomas by modulating the PI3K/AKT signaling pathway. (Biochemical and biophysical research communications, 2026, PMID 41966746): "Network pharmacology and transcriptomic analyses suggested that scutellarein may target SRC, EGFR, and AKT1; and exerts its effects through the PI3K/AKT signaling pathway, which was subsequently verified by further experiments."
• Jun Exploring the potential of heterocyclic-containing tail approach in the development of novel covalent inhibitors dual-targeting EGFR and HER-2: design, synthesis and biological evaluation. (Bioorganic & medicinal chemistry, 2026, PMID 41875675): "...to develop highly selective and low-toxicity EGFR/HER-2 dual-target covalent inhibitors."